Global Artificial Pancreas Systems Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Artificial Pancreas Systems market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Artificial Pancreas Systems market."
The artificial pancreas is a technology in development to help people with diabetes automatically control their blood glucose level by providing the substitute endocrine functionality of a healthy pancreas.
In terms of application, diabetes type 1 is the biggest downstream consummer in the global artificial pancreas system in 2017, accounting for a more than 90% share. And the revenue form this segement is estimated to see a CAGR of 13.21% from 2017 to 2025.

The global Artificial Pancreas Systems market is valued at 91 million US$ in 2018 is expected to reach 220 million US$ by the end of 2025, growing at a CAGR of 11.7% during 2019-2025.
This report focuses on Artificial Pancreas Systems volume and value at global level, regional level and company level. From a global perspective, this report represents overall Artificial Pancreas Systems market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Medtronic
    JDRF
    Tandem Diabetes Care
    Pancreum
    TypeZero Technologies
    Beta Bionics
    Johnson & Johnson
    Insulet Corp
    Bigfoot Biomedical
    Dexcom

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Control to Range (CTR) System
    Control to Target (CTT) System
    Threshold Suspended Device

Segment by Application
    Diabetes Type 1
    Diabetes Type 2